
Conference Coverage
3 days ago
ID Week Highlights Part 1Latest Content

Advertisement
Shorts

1:25
Why RSV Vaccine Recommendations Are More Complex Than Flu Shots
4 days ago
by
Robert H. Hopkins Jr. MD(+1 more)

0:35
Do the New Hepatitis B Birth Dose Guidelines Miss Horizontal Transmission?
5 days ago
by
Karen B. Jacobson, MD, MPH(+1 more)

0:32
Why Preserving Amikacin and Macrolide Susceptibility Matters in MAC Lung Disease
5 days ago
by
Kevin Winthrop, MD(+1 more)

1:11
Hepatitis B’s Hidden Household Risk for Infants
6 days ago
by
Karen B. Jacobson, MD, MPH(+1 more)

0:52
Should You Test MAC Isolates for Susceptibility Every Time?
6 days ago
by
Kevin Winthrop, MD(+1 more)

0:33
Why the Hepatitis B Birth Dose Is the Most Feasible Protection
7 days ago
by
Karen B. Jacobson, MD, MPH(+1 more)

0:36
Why ENCORE Tested Inhaled Amikacin From the Start of MAC Treatment
7 days ago
by
Kevin Winthrop, MD(+1 more)

1:32
Why People Put Off Vaccines—and How to Help Them Act
7 days ago
by
Robert H. Hopkins Jr. MD(+1 more)

0:57
Antibiogram Use at the Bedside
15 days ago
by
Zachary Nelson, PharmD, MPH, BCIDP(+1 more)

1:06
Utilizing the New UTI Classifications
18 days ago
by
Zachary Nelson, PharmD, MPH, BCIDP(+1 more)
Videos
Contagion Digital Edition

Recent urinary tract infection guideline updates from multiple international
medical societies highlight evolving recommendations, including a major shift
in classification, moving from anatomy- and risk factor–based definitions
toward distinguishing localized from systemic infections.

Widespread antimicrobial use disrupts vital microbial communities that regulate Earth’s biogeochemical cycles, driving antimicrobial resistance, worsening human and environmental health, and significantly contributing to climate change.

New data from the PETERPEN trial suggest that piperacillin-tazobactam may be noninferior to meropenem for early clinical outcomes in select patients with ESBL bloodstream infections, but carbapenems remain the standard of care until final mortality results are available and fully analyzed.

In mid-May, as the world was still grappling with an unexpected hantavirus outbreak aboard a tourism vessel, news broke of an Ebola outbreak in the Ituri Province of the Democratic Republic of the Congo spanning at least 3 health zones, including Bunia, Rwampara, and Mongbwalu.

Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.

A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.

A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.

Editor in chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the proposed OMB rule restricting federal grants for international research collaboration, and how it threatens infectious disease medicine's inherently borderless surveillance networks, publication access, and knowledge-sharing systems.

Daptomycin-resistant Enterococcus faecium bacteremia is an emerging, high-mortality challenge in transplant and other high-risk patients, requiring early recognition, aggressive source control, and reliance on limited alternatives—most notably linezolid—with combination or salvage therapies considered when options are constrained.
















































































